)

Pharmala Biotech Holdings (MDMA) investor relations material
Pharmala Biotech Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Revenue for the nine months ended May 31, 2025 was $338,122, down from $952,609 year-over-year, mainly due to fewer clinical trial shipments and loss of consulting revenue, partially offset by resumed SAP shipments in Canada.
Net loss for the nine months ended May 31, 2025 increased to $1,814,110 from $599,241 year-over-year, driven by higher operating expenses and increased stock-based compensation.
The company completed a $1.56M private placement in December 2024, strengthening its cash position and supporting ongoing R&D and working capital needs.
The company continues to focus on developing and commercializing MDMA and MDXX class molecules, with a strategic shift toward intellectual property-driven business lines.
Financial highlights
Gross profit for the nine months ended May 31, 2025 was $318,999, down from $655,647 year-over-year.
Total expenses rose to $2,117,495 from $1,085,458 year-over-year, with significant increases in payroll, research, and stock-based compensation.
Adjusted EBITDA loss for the nine months ended May 31, 2025 was $835,401, compared to a loss of $84,710 in the prior year period.
Cash at May 31, 2025 was $129,861, with an additional $1.1M in short-term investments.
No debt outstanding; all liabilities are short-term and non-interest bearing.
Outlook and guidance
Management expects future revenue growth as clinical trial shipments resume and SAP distribution expands, but cautions that revenue recognition is dependent on regulatory approvals and customer permit timing.
The company anticipates continued investment in R&D and intellectual property, with a focus on long-term value creation over short-term cash revenue.
Ongoing volatility in financial markets and regulatory changes in the psychedelics sector may impact future performance.
Next Pharmala Biotech Holdings earnings date

Next Pharmala Biotech Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage